207 related articles for article (PubMed ID: 29555634)
1. Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.
Bader JC; Lakota EA; Flanagan S; Ong V; Sandison T; Rubino CM; Bhavnani SM; Ambrose PG
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555634
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data.
Lakota EA; Ong V; Flanagan S; Rubino CM
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555631
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.
Lepak AJ; Zhao M; VanScoy B; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203480
[TBL] [Abstract][Full Text] [Related]
4. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy.
Miesel L; Lin KY; Ong V
Pharmacol Res Perspect; 2019 Dec; 7(6):e00546. PubMed ID: 31763045
[TBL] [Abstract][Full Text] [Related]
5. Outcomes by
Locke JB; Pillar CM; Castanheira M; Carvalhaes CG; Andes D; Aram JA; Andrzejewski C; Bartizal K; Das AF; Sandison T; Thompson GR; Pappas PG
Antimicrob Agents Chemother; 2024 May; 68(5):e0158423. PubMed ID: 38526046
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
Carvalhaes CG; Klauer AL; Rhomberg PR; Pfaller MA; Castanheira M
J Clin Microbiol; 2022 Apr; 60(4):e0244921. PubMed ID: 35249367
[TBL] [Abstract][Full Text] [Related]
7.
Zhao M; Lepak AJ; VanScoy B; Bader JC; Marchillo K; Vanhecker J; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378706
[TBL] [Abstract][Full Text] [Related]
8. Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481440
[TBL] [Abstract][Full Text] [Related]
9. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.
Lakota EA; Bader JC; Ong V; Bartizal K; Miesel L; Andes DR; Bhavnani SM; Rubino CM; Ambrose PG; Lepak AJ
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848022
[TBL] [Abstract][Full Text] [Related]
11. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.
Carvalhaes CG; Rhomberg PR; Pfaller MA; Locke JB; Castanheira M
Mycoses; 2022 Nov; 65(11):1040-1044. PubMed ID: 35778886
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181375
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation.
Xie J; Yang Q; Han X; Dong Y; Zhang T; Li Y; Ji M; Liu C; Cai Y; Wang Y
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0009922. PubMed ID: 35604209
[TBL] [Abstract][Full Text] [Related]
15. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
[TBL] [Abstract][Full Text] [Related]
16. We can do better: a fresh look at echinocandin dosing.
Bader JC; Bhavnani SM; Andes DR; Ambrose PG
J Antimicrob Chemother; 2018 Jan; 73(suppl_1):i44-i50. PubMed ID: 29304211
[TBL] [Abstract][Full Text] [Related]
17. EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.
Arendrup MC; Jørgensen KM; Hare RK; Cuenca-Estrella M; Zaragoza O
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285230
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections.
Rubino CM; Flanagan S
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084221. PubMed ID: 34398673
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.
Roepcke S; Passarell J; Walker H; Flanagan S
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0091623. PubMed ID: 38014945
[TBL] [Abstract][Full Text] [Related]
20. Rezafungin
Helleberg M; Jørgensen KM; Hare RK; Datcu R; Chowdhary A; Arendrup MC
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
